Serkova N - Search Results

1

Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.

Serkova N, Boros LG. Serkova N, et al. Am J Pharmacogenomics. 2005;5(5):293-302. doi: 10.2165/00129785-200505050-00002. Am J Pharmacogenomics. 2005. PMID: 16196499 Review.

2

Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.

Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ. Kominsky DJ, et al. Clin Cancer Res. 2009 May 15;15(10):3442-50. doi: 10.1158/1078-0432.CCR-08-3291. Epub 2009 Apr 28. Clin Cancer Res. 2009. PMID: 19401345

3

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ. Klawitter J, et al. Br J Pharmacol. 2009 Sep;158(2):588-600. doi: 10.1111/j.1476-5381.2009.00345.x. Epub 2009 Aug 6. Br J Pharmacol. 2009. PMID: 19663881 Free PMC article.

4

Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.

Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, Serkova NJ. Klawitter J, et al. Among authors: serkova nj. Br J Cancer. 2009 Mar 24;100(6):923-31. doi: 10.1038/sj.bjc.6604946. Epub 2009 Mar 3. Br J Cancer. 2009. PMID: 19259085 Free PMC article.

5

Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.

Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Klawitter J, et al. Among authors: serkova nj. Biomed Chromatogr. 2009 Dec;23(12):1251-8. doi: 10.1002/bmc.1247. Biomed Chromatogr. 2009. PMID: 19517424 Free PMC article.

6

Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J. Alvarez-Calderon F, et al. Clin Cancer Res. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29. Clin Cancer Res. 2015. PMID: 25547679 Free PMC article.

7

Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

Glunde K, Serkova NJ. Glunde K, et al. Pharmacogenomics. 2006 Oct;7(7):1109-23. doi: 10.2217/14622416.7.7.1109. Pharmacogenomics. 2006. PMID: 17054420 Review.

8

NMR-based metabolomics: translational application and treatment of cancer.

Serkova NJ, Spratlin JL, Eckhardt SG. Serkova NJ, et al. Curr Opin Mol Ther. 2007 Dec;9(6):572-85. Curr Opin Mol Ther. 2007. PMID: 18041668 Review.

9

Metabolic profiling of livers and blood from obese Zucker rats.

Serkova NJ, Jackman M, Brown JL, Liu T, Hirose R, Roberts JP, Maher JJ, Niemann CU. Serkova NJ, et al. J Hepatol. 2006 May;44(5):956-62. doi: 10.1016/j.jhep.2005.07.009. Epub 2005 Aug 2. J Hepatol. 2006. PMID: 16223541

10

Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Troiani T, et al. Clin Cancer Res. 2007 Nov 1;13(21):6450-8. doi: 10.1158/1078-0432.CCR-07-1094. Clin Cancer Res. 2007. PMID: 17975157

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

161 results

Search Page